Telomir Pharmaceuticals, Inc.

What they do

Telomir is a clinical-stage biotechnology company developing novel small-molecule therapeutics targeting biological pathways implicated in cancer. Its lead candidate, Telomir-Zn, is an oral small molecule designed to modulate intracellular metal homeostasis and epigenetic regulation, with the goal of influencing tumor biology. The company does not currently sell any approved products and reports no product revenue.

Revenue drivers

• Telomir-Zn (lead candidate) — Pre-revenue. The FDA has cleared the IND to initiate a clinical trial of Telomir-Zn in advanced or metastatic triple-negative breast cancer, but the candidate is not approved or commercialized.
• Telomir-1 (in-licensed pipeline) — Pre-revenue. Telomir-1 is in-licensed from MIRALOGX; the 10-K states the company does not own the underlying intellectual property rights and its rights depend on the license.
• Preclinical programs — Pre-revenue. The company continues preclinical research in animal and other model systems to evaluate Telomir-Zn across multiple disease areas.

Recent performance

Telomir reported net losses of $1.7 million for the three months ended June 30, 2026 and $5.1 million for the three months ended June 30, 2025. Net losses were $2.7 million for the six months ended June 30, 2026 versus $7.3 million for the six months ended June 30, 2025. Annual net income was -$854,147 in 2022, -$13.1 million in 2023, -$16.5 million in 2024 and -$10.4 million in 2025. Operating cash flow was -$468,661 in 2022, -$3.9 million in 2023, -$5.1 million in 2024 and -$3.7 million in 2025. Diluted EPS was -$0.56 in 2024 and -$0.33 in 2025, versus $0.48 in 2023 and -$0.03 in 2022.

Strategy

On April 22, 2026, the company completed its merger with TELI Pharmaceuticals, Inc., issuing 34,389,710 restricted shares to former TELI shareholders for exclusive worldwide rights to develop and commercialize Telomir-Zn. Bayshore Trust contributed $1.0 million at closing and committed up to $4.0 million more, tied to regulatory and clinical milestones. Under the funding commitment, FDA acceptance of the Telomir-Zn IND may trigger $2.0 million for 1,492,537 shares at a $1.34 reference price, and Phase 1/2 trial commencement may trigger another $2.0 million for 1,492,537 shares. Milestone share rights lapse if funding is not received within three months of the milestone event. Management expects research and development expenses to increase as the candidate advances into and through clinical trials.

Risks

• Early-stage, pre-revenue — The company has no approved or commercialized product and reported net losses of $2.7 million for the six months ended June 30, 2026.
• Reliance on licensed IP — The 10-K states Telomir-1 is in-licensed from MIRALOGX, that the company does not own the intellectual property rights to it, and that loss of the license could prevent it from selling the product.
• Clinical and regulatory uncertainty — The forward-looking statement list in the 10-K includes the ability to advance candidates into and successfully complete clinical trials, recruit and enroll suitable patients, and obtain and maintain regulatory approval.
• Need for additional financing — The 10-K lists the ability to obtain additional funding for operations and development activities and the need for additional financing among the factors affecting results.

Outlook

The company says FDA clearance of the IND allows it to initiate a clinical trial evaluating Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer, and it continues preclinical research across multiple disease areas. Management expects research and development expenses to increase as Telomir-Zn advances into and through clinical trials and as it evaluates acquiring or in-licensing additional candidates. It also states that the process of conducting the clinical trials needed for approval is costly and time-consuming and that it may never succeed in timely development or obtain regulatory approval.